Published on 19/03/2015 by admin
Filed under Dermatology
Last modified 19/03/2015
This article have been viewed 3147 times
Joanna E. Gach
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports
Jessner’s lymphocytic infiltrate (JLI) is a chronic inflammatory condition presenting with erythematous or reddish brown papules, annular or arciform plaques which can expand peripherally and sometimes develop central healing. The lesions are usually seen in adults and affect the face, neck, or upper trunk. Although they are frequently asymptomatic, some patients report itch or burning. The lesions can persist from weeks to years and disappear without sequelae, but may recur.
JLI runs a waxing and waning course marked by intermittent improvement and subsequent exacerbations, which makes the evaluations of therapeutic effectiveness difficult. Patients demand treatment because they find the lesions disfiguring or itchy.
Potent topical steroids applied once or twice daily for 4 weeks are the first-line treatment for many dermatologists. Unfortunately, the results of treatment are variable, and, most importantly, only short-lasting. If the response is inadequate, injection of intralesional corticosteroids into localized lesions or the use of potent topical steroid under occlusive dressing may be beneficial, but is associated with a greater risk of skin atrophy. Topical tacrolimus may be a safer alternative.
In cases where ultraviolet exposure has been reported to induce or exacerbate lesions, additional therapy with sunscreen may be needed. This group of patients may respond to antimalarials, in particular hydroxychloroquine.
A variety of other therapies have been reported to be effective in the management of JLI. Thalidomide, oral gold, and retinoids proved to be helpful in some cases, but their use may be limited by the adverse effects, which may be difficult for the patient and physician to accept, especially as JLI is harmless.
Many other treatments, including bismuth sub-salicylate injections, nicotinamide, vitamin E, phenindamine, para-aminobenzoic acid, penicillin, chlortetracycline, minocycline, dapsone, quinacrine (mepacrine), and radiotherapy, have been tried unsuccessfully.
Skin biopsy
Lesional skin for direct immunofluorescence
Antinuclear antibodies/extractable nuclear antigen
The diagnosis can be made on clinical grounds. The investigations are helpful in differentiating the condition from discoid lupus erythematosus, lupus erythematous tumidus, and cutaneous lymphoma.
Cerio R, Oliver GF, Jones EW, Winkelmann RK. J Am Acad Dermatol 1990; 23: 63–7.
Skin biopsy of the lesion shows normal epidermis and a moderate, dense sleeve-like perivascular and periadnexal infiltrate in the middle dermis. This consists of normal-looking lymphocytes with the B cells grouped in close proximity to the superficial vessels and T cells at the periphery, and occasional plasma cells.
Lipsker D, Mitschler A, Grosshans E, Cribier B. Dermatology 2006; 213: 15–22.
Immunofluorescence studies of lesional skin showed lupus band with IgG, IgM ± C3 in 9.5% of cases of JLI. Antinuclear antibodies were present in 45% of cases.
Toonstra J, Wildschut A, Boer J, Smeenk G, Willemze R, van der Putte SC, et al. Arch Dermatol 1989; 125: 1525–30.
Treatment of Skin Disease Comprehensive Therapeutic Strategies 4e
WhatsApp us